** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket
** LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus $(OLP)$, a chronic inflammatory disease that affects mucous membranes inside the mouth
** Co says no drug-related serious adverse events were found in study, and no patients dropped out
** LIPO says LP-310, an oral rinse topical treatment, helped meaningfully reduce pain, ulceration, and inflammation for patients in the study
** Co plans to submit marketing application for LP-310 to the FDA in H2 2025
** In the last 12 months, the stock has fallen 63.34%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。